# LB2102

Source: https://onco.cc/drugs/lb2102/  
OnCo record `lb2102` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

LB2102 is an experimental CAR-T cell therapy for small cell lung cancer, made from a patient's own immune cells and aimed at the protein DLL3. Legend Biotech licensed it to Novartis in November 2023.

## Summary

LB2102 is Legend Biotech's autologous CAR-T cell therapy directed at DLL3. On 13 November 2023 Legend announced an exclusive global licence giving Novartis worldwide rights to develop, manufacture and sell its DLL3 CAR-T therapies, including LB2102, with USD 100 million upfront; Novartis may make them on its T-Charge manufacturing platform, and Legend was to run the US phase 1 trial. The FDA cleared the investigational new drug application in 2022 and granted orphan drug designation in 2023. The phase 1 trial (NCT05680922), sponsored by Legend Biotech USA, started in July 2023 in extensive-stage small cell lung cancer and large cell neuroendocrine carcinoma of the lung, and the registry now lists it as active but no longer recruiting. No results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; deal-asset
- Modality: Autologous CAR-T cell therapy (DLL3)
- Mechanism: A patient's own T cells are collected and engineered with a chimeric antigen receptor that recognises DLL3, a protein on small cell lung cancer cells, then infused back to attack the cancer.

## Sources

- Legend Biotech and Novartis licence announcement, 13 November 2023 (Outsourced Pharma copy): https://www.outsourcedpharma.com/doc/legend-biotech-announces-exclusive-global-license-agreement-for-certain-car-t-therapies-targeting-dll-0001
- ClinicalTrials.gov: LB2102 phase 1 (NCT05680922): https://clinicaltrials.gov/study/NCT05680922

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- targets: [DLL3](https://onco.cc/targets/dll3/)
- companies: [Legend Biotech](https://onco.cc/companies/legend-biotech/), [Novartis](https://onco.cc/companies/novartis/)
- trials: [DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer](https://onco.cc/trials/nct05680922/)

---
JSON: https://onco.cc/api/v1/entities/lb2102.json